Early risk screening for Alzheimer's disease
Colloidal gold immunochromatography technology was used to qualitatively detect the Aβ concentration level in human urine, and the world's first AD urine test early screening reagent.
Product Features
- Early screening: Screening of people at high risk of Alzheimer
- Non-invasive: Non-invasive sampling urine test
- Hypersensitivity: Detection sensitivity up to picogram level
- Fast: Results can be reported 10 minutes after the sample is dropped
- Convenient: Add 100uL urine, easy to detect
- Accurate: The positive judgment value was 0.5ng/mL, and the detection rate was 95%
Product Application
- It can be applied to the regular physical examination population over 45 years old;
- Family history of dementia;
- Memory impairment and suspected cognitive impairment;
- Cardiovascular and cerebrovascular diseases and cerebrovascular injuries (stroke, cerebral hemorrhage, cerebral infarction, etc.);
- Chronic diseases (hypertension, diabetes, hyperlipidemia, etc.), snoring and homocysteine deficiency;
- Anxiety, depression, bad habits (smoking and drinking, lack of exercise in the middle of obesity, long-term lack of sleep, etc.).